A new drug approval or device clearance reaches the world as an announcement written for everyone at once: investors, patients, the trade press. Clintelo is written for the reader who has the least time for it and the most riding on it, the physician deciding between patients whether any of it changes practice.
The innovation floor that never closes
Physicians go to congresses to find out what is new, what the evidence says and how the options compare. Clintelo does that continuously. Each innovation is a brief that reads in under a minute: what it is, who it is for, what changes for patients, and how the evidence behind it was designed.
The feed covers new drugs and biologics, and new medical devices: implants, surgical systems, wearables, diagnostic tests, software and AI, and device-based procedures. You can read it by innovation type, by company, or by any of twenty physician specialties.
Clintelo, counted from the feed
Counted from the live feed each time this page is built.
One document behind every entry
Most medical news is a report of a report. By the time a new approval has been announced, covered and summarized again, the population, the trial design and the limits of the evidence are easy to lose. Clintelo goes back to the one document that carries them, and stays there.
Three rules every entry follows
One primary source
The FDA's own announcement, or the developer's own release. Not the news cycle, and not secondary reports.
Checked line by line
Entries are drafted with AI from that one document, then checked against it. No figure, date or claim is published that the source does not carry.
The source is one click away
Every entry links to the document it was written from, so the summary is never the last word.
Evidence marks describe how a study was designed. They do not grade the product.
Drug IQ and Device IQ, side by side
The two desks share one search and one way of working, and each speaks its own technology's language. Drug IQ opens a new drug approval as a 60-second brief: the bottom line for your patients, who it is for, what changes, the evidence, what to watch for, how it is given, and what the approval tells you.
Device IQ opens a device as a spec sheet that leads with its FDA route, so a cleared device reads as cleared, a De Novo as granted, and only an approved device as approved. Its class, setting and who uses it follow.
An announcement and a Clintelo entry
The announcement
- Written for
- Investors, patients and press at once
- Length
- As long as it needs
- Study design
- Described as the author chooses
- Where to check it
- Itself
The Clintelo entry
- Written for
- Physicians
- Length
- Reads in under a minute
- Study design
- Marked, or labelled “Design not reported”
- Where to check it
- Linked on the entry
| Written for | Length | Study design | Where to check it | |
|---|---|---|---|---|
| The announcement | Investors, patients and press at once | As long as it needs | Described as the author chooses | Itself |
| The Clintelo entry | Physicians | Reads in under a minute | Marked, or labelled “Design not reported” | Linked on the entry |
A description of format, not a judgment of any company's release. The Clintelo entry is written from the announcement.
Where Clintelo stops
When a source gives no trial figure, the brief says so instead of borrowing one. A cleared device is never called approved. Entries are chosen and written by Clintelo, and none is a paid placement. Clintelo is an information service for healthcare professionals: it is not medical advice, and it does not replace the full prescribing information or instructions for use.
What is live, and what is in the works
- Live
Drug IQ and Device IQ
Search new approvals, clearances and grants; each opens as a brief or a spec sheet.
- Live
Specialties and Compare
Twenty specialty pages, and two drugs or two devices compared line for line.
- Live
Ask Clintelo
A question answered only from the entries, with their sources.
- Live
My Clintelo
Your specialties and saved innovations, kept in this browser only.
- In the works
Accounts, alerts and the emailed brief
Not built yet. The early-access list below is how you will hear when they open.
Start with your specialty
- Pick your field on Specialties and see every new drug and device in it.
- Save what matters to My Clintelo. It stays in this browser; there is no account to create.
- Put two options side by side in Compare.
- Ask a question in Ask Clintelo and get an answer drawn only from the entries, with their sources.
If an entry says more than its source, or less than it should, tell us. Corrections are made on the entry itself.
Early access
Hear when accounts and alerts open
One email when accounts, alerts and the emailed brief open. Nothing else.
Sources and further reading
Frequently asked questions
What is Clintelo?
Clintelo is a medical innovation platform for physicians. It summarizes new FDA drug approvals and device decisions for practice, and links every entry to the primary source it was written from.
Where does Clintelo's information come from?
Each entry is written from one primary source: the FDA's own announcement or the developer's own release. No figure, date or claim is published that the source does not carry.
Does Clintelo use AI?
Yes. Entries are drafted with AI assistance from their source document, then checked line by line against it.
Is Clintelo medical advice?
No. Clintelo is an information service for healthcare professionals. It does not replace the full prescribing information or instructions for use.
Are any entries sponsored?
No. Entries are chosen and written by Clintelo, and none is a paid placement.
Written by the Clintelo team with AI assistance, from Clintelo's own published sourcing standards. Published . Clintelo is an information service for healthcare professionals, not medical advice.